Browsing: Mpox vaccine

• WHO’s move aims to galvanize a coordinated international response to contain and mitigate the spread of mpox.
• An uptick in cases, especially in Burundi, Kenya, Uganda, and Rwanda, along with sporadic cases in Europe, prompted the WHO’s emergency declaration.
• Despite these concerns, mpox is not likely to evolve into a pandemic akin to COVID-19.

Last week, the World Health Organization (WHO) declared mpox (formerly known as monkeypox) a Public Health Emergency of International Concern. This decision underscores the escalating threat posed by the virus, which surged globally in 2022 but has since seen a troubling resurgence, particularly in Africa. The WHO’s move aims to galvanize a coordinated international response to contain and mitigate the spread of mpox, a virus with significant public health implications.

Mpox, a member of the same viral family as smallpox, is a rare but severe infection. It manifests through symptoms akin to chickenpox, including fevers, swollen …

• Africa CDC has announced an ambitious alliance with vaccine maker Bavarian Nordic to secure 10 million doses of the mpox vaccine by the end of 2025.
• Vaccine maker Bavarian Nordic says it can supply up to 2 million doses by the end of 2024.
• Mpox outbreak has been particularly severe, prompting Africa CDC to declare it a PHECS on August 13, 2024.

In response to the escalating threat of mpox across the Africa, the Africa Centers for Disease Control and Prevention (Africa CDC) has announced an ambitious plan to secure 10 million doses of the mpox vaccine by the end of 2025.

This commitment comes in collaboration with Bavarian Nordic, a leading vaccine manufacturer, which has pledged to ramp up production and ensure the equitable distribution of vaccines.

The initiative is a critical step in tackling the ongoing mpox outbreak, which has been declared a Public Health Emergency of …